CONFERENCE COVERAGE
Dermatology Meeting News
Annual Meeting
2022 COVERAGE
- Topical Ruxolitinib Promising for Nonsegmental Vitiligo in Phase 3 Trials
- Severity of HS Associated With Age of Symptom Onset
- First Triple-Combination Acne Drug Well Tolerated
- Etanercept May Benefit Patients With Steven Johnson Syndrome
- Ruxolitinib Cream Effective, Well Tolerated Among Black Patients With Atopic Dermatitis
- Patients With Vitiligo Have Increased Mental Health Burden
- Ritlecitinib Treatment for Alopecia Areata Shows Early Response Rates
- Elevated CRP Associated With Poorer Outcomes, Mortality in Hidradenitis Suppurativa
- A Phase 3 Trial of Imsidolimab, a Monoclonal Antibody Therapy for Generalized Pustular Psoriasis
- Ocular Disease Risk Elevated in Patients With Rosacea and Diabetes
- Social Media as Medical and Patient Education Platforms for Dermatology
- Health Care Workers Report New, Exacerbated Acne With Mask Use During COVID-19 Pandemic
Latest Tweets
Follow
@DermAdvisor
Conference Coverage from
